Effect of Early Administration of TXA in Adult Hip Fractures
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This is a prospective clinical study designed to assess blood loss in intracapsular and
extracapsular hip fractures undergoing operative fixation at a Level II trauma center. It is
well established in the orthopedic literature that tranexamic acid (TXA) decreases blood loss
and need for postoperative blood transfusion in hip fracture patients as well as total joint
arthroplasty patients. A typical dosing pattern, and the dosing pattern employed at our
institution, is 1 gram IV infused prior to incision followed by 1 gram IV infused at the time
of wound closure.